Precision Medicine

Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.

Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)

December 10th 2024

Read More

Operationalization of Bispecific Antibodies in Non-Hodgkin Lymphoma (NHL)

Operationalization of Bispecific Antibodies in Non-Hodgkin Lymphoma (NHL)

September 30th 2024

Read More

Managing Anemia in Lower-Risk Myelodysplastic Syndromes (MDS)

Managing Anemia in Lower-Risk Myelodysplastic Syndromes (MDS)

Read More

Corey Cutler, MD, MPH, and Hannah Choe, MD

Treatment Options for Chronic GVHD (cGVHD): Evaluating Axatilimab (Anti-CSF-1R Antibody) Potential in Third Line or Greater

Read More

2 KOLs are featured in this series.

Weighing the Evidence: Immunomodulatory Combinations (IO/IO and IO/TKI) for the Treatment of Clear Cell Renal Cell Cancer

Read More

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

Evolving ADC-Directed Therapies for HER2-negative and HER2-low mBC

Read More

Rebecca A. Shatsky, MD, an expert on breast cancer

The Evolving Role of HER2-Targeting Therapies in Breast Cancer

March 22nd 2024

Read More

Patrick Forde, MBBCh, an expert on lung cancer

Treatment Strategies in Early NSCLC: The Role of Immunotherapy

December 13th 2023

Read More

$Evaluating Ruxolitinib in Steroid Refractory Chronic GvHD$

Evaluating Ruxolitinib in Steroid Refractory Chronic GvHD

December 13th 2023

Read More

Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS

Insights into the Evolving Disease and Treatment Landscape of Lower-Risk MDS

December 13th 2023

Read More

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

The Evolving Role of ADCs in NSCLC: A Focus on TROP2-Directed Therapies

November 15th 2023

Read More

Experts on GI Cancer

Recent Updates in the Management of Gastrointestinal Malignancies

October 6th 2023

Read More

A Collaborative Approach to the Treatment and Management of Advanced Prostate Cancer

A Collaborative Approach to the Treatment and Management of Advanced Prostate Cancer

September 29th 2023

Read More

Expert on NSCLC

Evolving Strategies for Treating Metastatic Non-Small Cell Lung Cancer: Focus on TROP2-Directed ADCs

September 29th 2023

Read More

The Evolving Treatment Landscape of Lower-Risk MDS

The Evolving Treatment Landscape of Lower-Risk MDS

Read More

Updates in the Treatment of Advanced Renal Cell Carcinoma

Updates in the Treatment of Advanced Renal Cell Carcinoma

Read More

CEACAM5: An Emerging Therapeutic Target in Non-small Cell Lung Cancer

CEACAM5: An Emerging Therapeutic Target in Non-small Cell Lung Cancer

Read More

Expert on MM

Evaluating XPO1 Inhibitors in Multiple Myeloma and their Potential Role in Myelofibrosis

December 22nd 2022

Read More

The Evolving Treatment Paradigm for Patients with KRASG12C Mutated NSCLC and CNS Metastases

The Evolving Treatment Paradigm for Patients with KRASG12C Mutated NSCLC and CNS Metastases

December 20th 2022

Read More

Experts on FL

Bispecific Antibodies for Follicular Lymphoma

December 2nd 2022

Read More

Experts on MPNs

Targeted Treatments for Myeloproliferative Neoplasms

October 28th 2022

Read More

Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

September 29th 2022

Read More

Experts on RCC

Evidence-Based Strategies for Selecting the Appropriate Frontline Therapy in Advanced RCC

September 16th 2022

Read More

Frontline Treatment of Acute Myeloid Leukemia

Frontline Treatment of Acute Myeloid Leukemia

Read More

BCL-2 Family Proteins as Therapeutic Targets in Multiple Myeloma

BCL-2 Family Proteins as Therapeutic Targets in Multiple Myeloma

Read More

ALK Gene Rearrangements As A Therapeutic Target in Non-small Cell Lung Cancer

ALK Gene Rearrangements As A Therapeutic Target in Non-small Cell Lung Cancer

November 23rd 2021

Read More

hematologists

CD19 as a Target in the Treatment of DLBCL

October 29th 2021

Read More

The Changing Landscape of Chronic Graft vs. Host Disease

The Changing Landscape of Chronic Graft vs. Host Disease

October 8th 2021

Read More

Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted Therapy

Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted Therapy

September 30th 2021

Read More

$The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL$

The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

September 15th 2021

Read More

CancerNetwork.com

OncNursingNews.com

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.